What is also unclear is whether certain molecular features or cytogenetic changes, such as MLL rearrangement (as in this case) or p53 deletion predisposes a subpopulation of AML patients to develop extramedullary disease, particularly in the CNS or eye which can cause major morbidity. The gene discussed is TP53; the disease is acute myeloid leukemia.